Metabolic signature of eyelid basal cell carcinoma
| Autor: | Lauren V. Gioia, John Nguyen, Jiancheng Huang, Shanawar Waris, Yekai Wang, Jamie Lea Schaefer, Chen Zhao, Ying Pei, Jianhai Du, Xiaofei Shi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male Nicotinamide adenine dinucleotide Eyelid Neoplasms Article 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine medicine Metabolome Biomarkers Tumor Humans Metabolomics Basal cell carcinoma skin and connective tissue diseases Aged Nicotinamide integumentary system Metabolism medicine.disease Sensory Systems eye diseases body regions Ophthalmology 030104 developmental biology medicine.anatomical_structure chemistry Carcinoma Basal Cell Nicotinamide riboside 030221 ophthalmology & optometry Cancer research Female NAD+ kinase Eyelid sense organs |
| Zdroj: | Exp Eye Res |
| ISSN: | 1096-0007 |
| Popis: | Purpose Eyelid basal cell carcinoma (BCC) is the most common eyelid malignancy. Metabolic reprogramming is critical in tumorigenesis, but the metabolic feature of eyelid BCC remains elusive. In this study, we aim to reveal the metabolic profile in eyelid BCC using targeted metabolomics. Eyelid samples were collected from patients who had removal of BCC and from control patients who underwent blepharoplasty. Multivariate analysis of metabolomics data distinguished the two groups, indicating that eyelid BCC has significantly different metabolome than the healthy tissue. We found 16 increased and 11 decreased metabolites in the BCC tissues. These metabolites were highly enriched in the metabolism of nicotinamide adenine dinucleotide (NAD), glutathione metabolism, polyamine metabolism, and the metabolism of glycine, serine, threonine, arginine and proline. amino acid metabolism. Metabolites from NAD metabolism (Nicotinamide; Nicotinamide riboside; N1-Methylnicotinamide) had the highest sensitivity, specificity, and prediction accuracy in a prediction model for eyelid BCC. In conclusion, eyelid BCC has a signature change of cell metabolome. Metabolites in NAD metabolic pathways could potentially be biomarkers or therapeutic targets for eyelid BCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect